No-Flush Niacin (Inositol Hexanicotinate) 500 mg
Product analysis
No-Flush Niacin (Inositol Hexanicotinate) 500 mg offers a low-cost niacin-focused supplement. Its no-flush preparation cannot be assumed to share the blood-lipid effects of nicotinic acid, limiting its appeal for that purpose.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality20
The no-flush description identifies a different preparation from nicotinic acid. Incomplete separate form details limit a firm comparison of the niacin and inositol contributions.
Ingredient Transparency63
Niacin and inositol amounts are stated. Their separate form entries are incomplete, so the compound name should not be used to infer nutrient yield.
Value For Money100
The labeled niacin serving is inexpensive. That price advantage does not establish equivalence to other niacin preparations.
Customer Satisfaction80
Ratings indicate very high satisfaction. The feedback base is useful but smaller than for heavily reviewed supplements.
Product Focus67
The formula stays focused on niacin-related use. Its cardiovascular relevance is limited because the no-flush preparation does not establish the effects associated with nicotinic acid.
- Format
Capsule - Container
- 100 Capsule(s)
- Per serving
- $0.18
- Customer rating
- 4.8 · 581 ratings
Goals
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Niacin | 400 mg | |
Inositol | 100 mg |
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
- Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
- Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
- Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
- Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
- Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
- The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
- The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
- Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
- Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.